TrialClinical cancer research : an official journal of the American Association for Cancer Research2024

Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients.

Sara M Tolaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.